Investigation Report on China Ranibizumab Market, 2012-2019
|出版商||China Research and Intelligence||商品編碼||336268|
|出版日期||內容資訊||英文 20 Pages
|Ranibizumab的中國市場分析 Investigation Report on China Ranibizumab Market, 2012-2019|
|出版日期: 2015年07月24日||內容資訊: 英文 20 Pages||
Ranibizumab是老齡化的黃斑變種 (AMD) 的治療藥，中國在2012年由CFDA (國家食品藥品監督管理總局)認證。現在上市的只有是Lucentis (Novartis開發)，不過，2013年12月國內廠商自主開發的治療藥也受認證。Ranibizumab市場轉向上市急速擴大，在國內19處醫院的銷售額是2億4500萬人民幣 (2014年)，過去3年的市場成長率達到200％。
As macular is the area responsible for high-resolution vision near the center of the retina, macular degeneration, once occurred, will lead to a loss of central vision and distorted vision in the form of metamorphopsia or even irreversible blindness. According to a report published by WHO in 2012, 30 million people suffer from macular degeneration globally, among which about 500,000 end up in blindness per year. In the US, blindness cases caused by macular degeneration outnumbers those caused by glaucoma, cataract and diabetic retinopathy. According to a Chinese investigation in 2012, the incidence of macular degeneration reaches up to 15.5% among old people aged above 50 and 20.2% among those aged above 70. With ageing population, the incidence of macular degeneration will continue to go up.
Developed by Novartis, ranibizumab was approved by CFDA to treat wet age-related macular degeneration (AMD) in 2012. Currently, only Lucentis, a product of Novartis, is available in the Chinese market. However, in Dec. 2013, as the first self-developed drug for the treatment of wet AMD in China, conbercept ophthalmic injection got CFDA's approval.
Ranibizumab develops fast after entering China, sales value in 19 sample hospitals in key cities in 2014 reaching CNY 245 million with a year-on-year growth of 26.29% and CAGR during the last three years reaching 200%. With ageing population, the incidence of macular degeneration goes up gradually. Hence the vast demand for ranibizumab in China. Currently, ranibizumab injections in mainland China all come from Novatis. But as conbercept ophthalmic injection is proved by the clinical studies to improve vision better with a lower administration frequency, it is expected to break the monopoly of Novatis in the wet AMD drug market in the next few years.